Hypothyroidism

Crash diets may work against you – and could have permanent consequences

Retrieved on: 
화요일, 1월 2, 2024
Hypothyroidism, Metabolism, Fatigue, Research, Weight, Hormone, Fats, Weight loss, Diet, Crash, Mitochondrion, Digestion, Obesity, Food, Weight gain, Social media, Human, Carbohydrate, Time, Thyroid, Exercise, Dietary supplement

Crash diets have been around for years, but have stayed popular more recently thanks to influencers and social media.

Key Points: 
  • Crash diets have been around for years, but have stayed popular more recently thanks to influencers and social media.
  • Typically, these diets involve drastically reducing calorie intake to 800-1,200 calories a day for a few weeks at a time.
  • Proponents of these diets claim it can lead to rapid weight loss, which may explain why they have such a significant appeal.
  • But while these diets may lead to short-term weight loss success in some people, they can have the long-term consequence of damaging your metabolism.

Crash diets and metabolism

  • Your metabolism is affected by many things – including diet, exercise and your hormones.
  • Crash diets affect all these components.
  • In the short-term, crash diets can lead to feelings of tiredness, which makes doing any activity (let alone a workout) challenging.
  • In the long term, crash diets can change the hormone makeup of our bodies.
  • And over an extended period of time, typically months, high cortisol levels can cause our body to store more fat.
  • Crash diets can also reduce levels of the hormone T3, which is produced by the thyroid gland.

Gradual dieting

  • If you’re trying to lose weight, the best strategy to use is following a long-term, gradual weight loss diet.
  • Gradual diets have been shown to be more sustainable and have a less negative impact on your metabolic rate compared with crash diets.
  • Gradual diets can also help maintain energy levels enough to exercise, which can help you lose weight.
  • This creates a greater capacity for burning calories even after we finish dieting.


Christopher Gaffney receives research funding from Omega EFA Limited.

Food And Drug Administration Grants Two New Label Changes To Tirosint®-Sol (Levothyroxine Sodium) Oral Solution

Retrieved on: 
월요일, 12월 4, 2023
Biotechnology, FDA, Managed Care, Health, General Health, Women, Seniors, Pharmaceutical, Research, Consumer, Science, Breakfast, Heat intolerance, Absorption, Food, Hypothyroidism, Eating, Commercial Operating System, Irritability, Headache, Risk, Tremor, Arrhythmia, IBSA, Rash, Cardiovascular disease, Insurance, Patient, Diabetes, Myocardial infarction, Periodic breathing, Appetite, Atrial fibrillation, Muscle weakness, Enzyme inhibitor, Adrenal insufficiency, Diarrhea, Menstruation, University, Water, Insomnia, PPI, Glycerol, Common, Spasm, Nervous, Hyperthyroidism, Weight loss, Pharmacy, Pharmaceutical industry, Dietary supplement, Levothyroxine

The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism.
  • The first regards the use of Tirosint-SOL in the presence of proton pump inhibitor (PPI) therapy.
  • Both label changes help to differentiate Tirosint-SOL from other levothyroxine therapies.
  • Similarly, current labeling for all levothyroxine sodium therapies instructs patients to self-administer the drug once daily, on an empty stomach, one-half to one hour before breakfast.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Retrieved on: 
수요일, 11월 1, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Survival, Patient, Colitis, Nephritis, Cholangiocarcinoma, Incidence, Hypothyroidism, Pneumonitis, NYSE, Food, Progression-free survival, Fatigue, Medicine, Itch, DOR, AST, Pembrolizumab, Cisplatin, Head, Gastrointestinal cancer, MRK, PFS, Fever, University of California, Bile, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIV disease progression rates, Administration, Rash, Disease, Ascending cholangitis, Merck & Co., Risk, Immunotherapy, ORR, University, Anemia, RECIST, BTC, Hepatitis, Biliary tract, Lymphocyte, ALT, OS, Death, Toxicity, Hematopoietic stem cell transplantation, CI, Pharmaceutical industry, Vaccine, Merck

Median OS was 12.7 months (95% CI, 11.5-13.6) for KEYTRUDA plus chemotherapy versus 10.9 months (95% CI, 9.9-11.6) for chemotherapy alone.

Key Points: 
  • Median OS was 12.7 months (95% CI, 11.5-13.6) for KEYTRUDA plus chemotherapy versus 10.9 months (95% CI, 9.9-11.6) for chemotherapy alone.
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • For gemcitabine, treatment could be continued beyond eight cycles, while for cisplatin, treatment could be administered for a maximum of eight cycles.
  • There was a difference of ≥5% incidence in laboratory abnormalities between patients who received KEYTRUDA plus chemotherapy versus placebo plus chemotherapy for decreased lymphocytes (69% vs. 61%).

The Importance of Progesterone Testing Before Dog Pregnancy

Retrieved on: 
월요일, 10월 30, 2023
Female, Veterinarian, Hypothyroidism, Health, Progesterone, Pet, Fertilisation, Mung bean, PCOD, Anomaly scan, Pregnancy, Breeding, Risk, Ovulation, Travel, Green bean, Corpus luteum, Dog, Meigs's syndrome, Bluetooth, Birth control, Video game, Amazon

NEW YORK, Oct. 30, 2023 /PRNewswire-PRWeb/ -- MongGoQ: Progesterone is a hormone that plays a crucial role in the reproductive system of pets,primarily dogs. During pregnancy, progesterone levels rise to support the developing fetus and prepare the mother's body for birth. Before pregnancy, progesterone testing can provide valuable information about the health of the pet and the potential for successful pregnancy.

Key Points: 
  • Before pregnancy, progesterone testing can provide valuable information about the health of the pet and the potential for successful pregnancy.
  • Before pregnancy, progesterone testing can provide valuable information about the health of the pet and the potential for successful pregnancy.
  • Monggoq Dog Progesterone Detector is used to detect the secretion of progesterone in dogs, which plays an important role in female dog reproductive activities, such as ovulation, maintaining pregnancy, delivery, and breast development.
  • Progesterone testing before pregnancy can also indicate any potential fertility issues that may affect a pet's ability to conceive.

Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
금요일, 10월 20, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Bevacizumab, Neoplasm, FDA, Arm, PD-L1, Standard of care, Cervical cancer, Gynaecology, Hypothyroidism, Catholic higher education, Aes, NYSE, ESMO, Progression-free survival, Food, Trae tha Truth, Cisplatin, Congress, Chemoradiotherapy, MRK, PFS, European Society for Medical Oncology, Obstetrics, GOG, Brachytherapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, HIV disease progression rates, Creighton University School of Medicine, CPS, ClinicalTrials.gov, Merck & Co., Risk, EBRT, Immunotherapy, University, European Network for Health Technology Assessment, Woman, Safety, European Society of Gynaecological Oncology, Cancer, Patient, OS, Death, Pharmaceutical industry, Merck

Results from the trial showed that KEYTRUDA in combination with concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone for these patients.

Key Points: 
  • Results from the trial showed that KEYTRUDA in combination with concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone for these patients.
  • ET during a late-breaking abstract proffered paper session at the European Society for Medical Oncology (ESMO) Congress 2023 (abstract #LBA38).
  • After a median follow-up of 17.9 months (range, 0.9-31.0), the KEYTRUDA regimen reduced the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.55-0.89]; p=0.0020) versus concurrent chemoradiotherapy alone in these patients.
  • The 24-month PFS rate was 67.8% for patients who received the KEYTRUDA regimen compared to 57.3% for those who received concurrent chemoradiotherapy alone.

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Retrieved on: 
금요일, 10월 20, 2023
Research, Surgery, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, MSD, Principal, Neoplasm, PD-L1, Trastuzumab, Hypothyroidism, Aes, NYSE, ESMO, Progression-free survival, Food, Trae Waynes, European Commission, Oxaliplatin, DOR, HER2, Cisplatin, Congress, Head, ITT, MRK, European Society for Medical Oncology, PFS, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIV disease progression rates, Capecitabine, CPS, Civil service commission, Memorial Sloan Kettering Cancer Center, Merck & Co., Risk, RECIST, Safety, European Society of Gynaecological Oncology, Cancer, GEJ, Patient, OS, Death, Pharmaceutical industry, Medical imaging, Merck, ORR

Based on a pre-specified subgroup analysis, the improvement in PFS observed in the ITT population was limited to patients whose tumors expressed PD-L1 (CPS ≥1).

Key Points: 
  • Based on a pre-specified subgroup analysis, the improvement in PFS observed in the ITT population was limited to patients whose tumors expressed PD-L1 (CPS ≥1).
  • In the study, more than 80% of patients’ tumors expressed PD-L1 (CPS ≥1).
  • The most common of these events (occurring in ≥10% of patients) were infusion reactions (16.6%) and hypothyroidism (10.3%).
  • Immune-mediated AEs and infusion reactions that led to discontinuation of any study treatment occurred in 7% of patients receiving the KEYTRUDA regimen and 4% of patients receiving trastuzumab and chemotherapy alone.

Allara Raises $10M in Series A Funding Led by GV (Google Ventures) to Bridge the Care Gap for Women with Chronic Hormonal Conditions

Retrieved on: 
수요일, 10월 18, 2023
Fertility, Digital, Woman, Insurance, Hypothyroidism, Health, Obesity, GV (company), PCOS, Diabetes, 1Life Healthcare, Nature, Pregnancy, GV, Polycystic ovary syndrome, Patient, Diagnosis, Endometriosis, Infertility, Birth control

NEW YORK, Oct. 18, 2023 /PRNewswire/ -- Allara, a first-of-its-kind virtual care platform bridging the care divide for the millions of women of reproductive age dealing with chronic hormonal conditions, today announced $10 million in Series A funding led by GV (Google Ventures), with participation from Great Oaks Venture Capital, Humbition, Vanterra, Gaingels, and individual investors, including Tom Lee (One Medical) and Maggie Sellers. GV General Partner Frédérique Dame also joins Allara's Board of Directors.

Key Points: 
  • Allara's pioneering care platform pairs patients with specially trained expert doctors and registered dietitians for ongoing care to fill a significant gap in women's healthcare.
  • Over 1 in 3 women live with a chronic condition such as polycystic ovary syndrome (PCOS), endometriosis, or hypothyroidism.
  • Allara recognized these gaps as a call to help women with chronic conditions feel seen, heard, and treated with specialized care.
  • "Women of reproductive age have complex hormonal care needs, and Allara raises the bar for clinically driven, personalized hormonal healthcare," said GV General Partner Frédérique Dame.

Sernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting

Retrieved on: 
금요일, 9월 29, 2023
Thyroid hormones, TSH, American Thyroid Association, Histology, Depression, FSE, ATA, FT4, Quality of life, PSH, Hypothyroidism, Weight gain, Thyroidectomy, Triiodothyronine, Patient, Cell, Annual general meeting, TSX, Poster, Memory, Fatigue, Thyroid, Medical imaging, Pharmaceutical industry

Thyroid stimulating hormone (TSH) levels had a significant peak immediately after thyroidectomy, with a gradual decline observed starting five weeks after the re-implantation of thyroid glands.

Key Points: 
  • Thyroid stimulating hormone (TSH) levels had a significant peak immediately after thyroidectomy, with a gradual decline observed starting five weeks after the re-implantation of thyroid glands.
  • Newly reported radio-isotope uptake imaging and histology assessments confirmed the presence of healthy and functional thyroid tissues within the Cell Pouch six months following re-implantation.
  • “With Sernova’s Cell Pouch System, we aim to improve quality of life with a treatment for post-operative hypothyroidism.
  • These new data replicate a human clinical scenario in which thyroid tissue is reimplanted into the patient, via the Cell Pouch, leading to the restoration of normal thyroid function.

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Retrieved on: 
금요일, 5월 26, 2023
MSD, Senior, Hepatocellular carcinoma, Pharming, Sunitinib, Survival, Head, DO, Cancer, Patient, Stomatitis, Risk, Merck, Fatigue, Texas Oncology, Diarrhea, Pembrolizumab, FACP, Research, Lung cancer, Merck & Co., Hypertension, LEAP, HIV disease progression rates, Esophageal cancer, Abstract, Death, Apoptosis, Lenvatinib, Overalls, PFS, Eisai, CR, Stomach, ORR, Acral lentiginous melanoma, Arm, Progression-free survival, RCC, CI, OS, Drug, Trae tha Truth, Hypothyroidism, ASCO, Central Time Zone, American Society of Clinical Oncology, Cancer Treatment Centers of America, Physician, Annual general meeting, Nausea, Society, Pharmaceutical industry, EU

After four years of follow-up, LENVIMA plus KEYTRUDA maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21% (HR=0.79 [95% CI, 0.63-0.99]).

Key Points: 
  • After four years of follow-up, LENVIMA plus KEYTRUDA maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21% (HR=0.79 [95% CI, 0.63-0.99]).
  • The 24- and 36-month estimated OS rates were 80.4% and 66.4% for LENVIMA plus KEYTRUDA versus 69.6% and 60.2% for sunitinib, respectively.
  • Grade ≥3 treatment-related adverse events (TRAE) occurred in 74.1% of patients who received LENVIMA plus KEYTRUDA versus 60.3% of patients who received sunitinib.
  • These findings reinforce the important role of LENVIMA plus KEYTRUDA as a first-line standard of care treatment option for patients with advanced renal cell carcinoma."

Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Retrieved on: 
월요일, 7월 31, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Orbis, GSK, Priority review, US Foods, Risk, Prescription Drug User Fee Act, Radiation, Society, SGO, Senior, Diarrhea, Society of Gynecologic Oncology, The New England Journal of Medicine, ESMO, European Medicines Agency, Clinical trial, Paclitaxel, Hope, Gynecologic Oncology (journal), Part, Carboplatin, Hypothyroidism, European Society for Medical Oncology, PFS, Rash, Hypertension, GSK plc, Endometrial cancer, HIV disease progression rates, MD, Patient, Division, FORCE, Annual general meeting, Washington University School of Medicine, United Kingdom, European Society of Gynaecological Oncology, ITT, Death, III, News, Food, Safety, Pharmaceutical industry, Dostarlimab

Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said: “Today’s expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Key Points: 
  • Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said: “Today’s expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
  • Until now, chemotherapy alone has been the standard of care with many patients experiencing disease progression.
  • These results and today’s approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy.”
    With this approval, Jemperli is now indicated earlier in treatment in combination with chemotherapy for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
  • The most common treatment-emergent adverse events (≥ 20%) in patients receiving Jemperli plus chemotherapy were rash, diarrhea, hypothyroidism and hypertension.